The Chinese company Sinopharm has reportedly sought Pakistan’s permission for the deployment of its COVID-19 vaccine in case of an emergency.
Five companies have already applied for a license to distribute their vaccines, following their approvals.
The United Arab Emirates had held trials for the Chinese vaccine in December 2020 and had concluded that the Sinopharm produce was 86 percent effective against the symptoms of the coronavirus.
Sinopharm has affirmed its intention for potential vaccine rollouts in Pakistan by registering with the Drug Regulatory Authority of Pakistan (DRAP) for approval.
As per sources, data pertaining to clinical trials and microbiological efficacy have been shared with the DRAP, pending approval in an upcoming session of the registration board that is expected to be held within a fortnight.
Sinopharm is currently working on two COVID-19 vaccines based on a similar synthetic model, and upon gaining approval, it will distribute its vaccine to developing healthcare centers across Pakistan.
With gargantuan pharmaceutical companies having initiated the first phase for the rollout of the COVID-19 vaccine, mostly moderate economies such as Pakistan will have to wait for the well-to-do countries to get it first.
Pakistan is currently running Phase-III clinical trials for the CanSino Biologics vaccine which is another Chinese product that has been developed under the supervision of the National Institute of Health (NIH).